Want to quit smoking? Try this vaccine

0
1079

Smoking addiction is a serious problem in this modern era. Smoking leads to lung cancer, pancreatic cancer and other cancers. Scientists from The Scripps Research Institute (TSRI) have designed an effective nicotine vaccine. The study was published recently in the Journal of Medicinal Chemistry. “This study provides new hope that one could make a nicotine vaccine that succeeds in clinical trials,” said Kim Janda, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. Nicotine vaccines train the body to see nicotine as a foreign invader. To prompt this immune response, nicotine derivatives called haptens are attached to a larger carrier protein used in other approved vaccines. The body reacts to the vaccine by creating antibodies to bind specifically to nicotine molecules. When a person later uses tobacco, the anti-nicotine antibodies stop the nicotine molecules from entering the central nervous system and ever reaching the brain. The researchers believe purifying nicotine hapten mixtures is an important and practical step in creating future nicotine vaccines.

Source:

This article is based on materials provided by: http://www.scripps.edu/news/press/2015/20150112janda.html

The original article can be accessed at: http://pubs.acs.org/doi/abs/10.1021/jm501625j

Disclaimer: This article does not reflect any personal views of the authors/editors

Previous articleScientists identify a new target for the treatment of acute myeloid leukaemia (AML)
Next articleContracting human muscle grown in lab for the first time
Scientist-entrepreneur-manager-journalist: -Co-founder, Author; Former Assistant Editor and Director, Biotechin.Asia, Biotech Media Pte. Ltd.; -Founder & CEO, SciGlo (www.sciglo.com); -Programme Management Officer, SBIC, A*STAR (former Research Fellow). --Sandhya graduated from University of Madras, India (B.Sc Microbiology and M.Sc Biotechnology) and received her Ph.D from the Nanyang Technological University, Singapore. She worked on oxidative stress in skin, skeletal, adipose tissue and cardiac muscle for a decade from 2006-2016. She is currently working as a Programme Management Officer handling projects and grants at Singapore Bioimaging Consortium (SBIC), Agency for Science, Technology and Research (A*STAR). Earlier to this she was a Research Fellow in the Fat Metabolism and Stem Cell Group at SBIC. Sandhya was also the Vice President and Publicity Chair of A*PECSS (A*STAR Post Doc Society) (2014-2016). Recently she founded a platform for scientists - SciGlo (www.sciglo.com) and is a startup mentor at Vertical VC (Finland). She is an ardent lover of science and enjoys globe trotting and good vegetarian food.